Rapid Update 1- March 2018: Type 2 diabetes: observational study investigates cardiovascular outcomes and amputation risks with sodium glucose co-transporter 2 inhibitors

This content is available to authorised users working in organisations that subscribe to ScriptSwitch only. Authorised users need to be logged in to read this content.

Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.

Rapid Update 3- August 2017: Type 2 diabetes: potential cardiovascular benefits with the SGLT2 inhibitor canagliflozin but with a greater risk of amputation

This content is available to authorised users working in organisations that subscribe to ScriptSwitch only. Authorised users need to be logged in to read this content.

Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.

Liraglutide: Cardiovascular outcome data in type 2 diabetes (Aug-16)

This content is available to authorised users working in organisations that subscribe to ScriptSwitch only. Authorised users need to be logged in to read this content.

Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.

Type 2 Diabetes: cohort study finds that compared with other antidiabetic drugs, sitagliptin and saxagliptin do not increase the risk of heart failure (May-16)

This content is available to authorised users working in organisations that subscribe to ScriptSwitch only. Authorised users need to be logged in to read this content.

Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.

Updated NICE guidance on Type-2 Diabetes – recommendations on drug treatments (Jan-16)

This content is available to authorised users working in organisations that subscribe to ScriptSwitch only. Authorised users need to be logged in to read this content.

Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.